As per our report, the size of the global extracorporeal membrane oxygenation machine market is anticipated to grow at a 4.34% CAGR from 2024 to 2029. The market was worth USD 318.62 Million in 2024 and is expected to reach USD 394.03 Million by 2029.
So that the growth of ECMO in countries like India and China is significant in the coming future. According to the United Nations, 426 million people aged above 80 years suffer from respiratory disease by 2020, which was 143 million in 2019. As well as the rising healthcare expenditure by government and private agencies to improve healthcare facilities are boosting the market.
ECMO market is one of the eye-catching segments aftermaths of COVID-19. The rise in the geriatric population, increase in respiratory diseases, the prevalence of breathing disorders, and increase in pollution are the main factors driving the market for further expansion.
There are many opportunities for the market to grow; they are like an increase in the geriatric population worldwide. As per the reports of WHO, the world population aging rate is very high. In countries like India, China, and South Africa, there is an increase in pollution percentage, putting more people at risk for respiratory infections. These countries offer a lucrative market for the expansion of this ECMO equipment.
Moreover, the lack of skilled professionals and the high cost of the therapies are the challenges of the extracorporeal membrane oxygenation machines market.
Few challenges are to be addressed for effective penetration of the market. Lack of skilled force, there are few complications associated with these devices. There is more chance of respiratory infections with the use of these machines. This is the major challenge that needs to be addressed.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Modality, Application, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
Market Leaders Profiled |
Getinge Group, Medtronic plc, LivaNova PLC, XENIOS AG, Terumo Corporation, MicroPort Scientific Corporation, NIPRO Corporation, OriGen Biomedical Inc., ALung Technologies Inc., and EUROSETS S.r.l. |
The venovenous (VV) segment is expected to account for the largest share of this market segment based on modality. The large share of this segment is primarily due to the high incidences of respiratory failure, rise in lung transplants, and technological advancements. The arteriovenous (AV) segment is projected to grow at the highest CAGR in the coming years.
Based on application, the respiratory segment accounts for the largest share of this market segment. The large share of this segment can be credited to factors such as a rise in respiratory failure, lung cancer, lung transplants, and increasing adoption of ECMO.
Geographically, North America held the largest share in the global ECMO market in 2023. The North America Extracorporeal Membrane Oxygenation Machine Market was valued at USD 108.40 million in 2024 and is anticipated to reach USD 130.50 million at a CAGR of 4.12% during the forecast period. The growth of the market was attributed to the rising number of cardiovascular and respiratory diseases. The surging number of ECMO centers in North America is propelling market growth. The major contributor to the North American market was the United States. The rise in the prevalence of asthma and heart failure is fueling the US market. For instance, more than 5.7 million adults in the United States die of heart failure every year. Rising occurrences of swine flu and acceptable reimbursement policies lead to ECMO machines' adoption in hospitals and clinics. Canada is predominantly expanding year by year during the forecast period.
The Asia-Pacific market was the second leading market after North America. The Extracorporeal Membrane Oxygenation Machine Market in the Asia Pacific was valued at USD 72.49 million in 2024 and is awaited to reach USD 98.07 million by 2029 at a CAGR of 5.45% during the forecast period. The presence of a high population and high incidence of severe cardiorespiratory conditions are driving the Asia Pacific Extracorporeal Membrane Oxygenation Machine Market. China, Japan, Australia, and India are the contributors to the Extracorporeal Membrane Oxygenation Machine Market. The favorable reimbursement scenario in Japan, rising cardiovascular diseases in China, growing application and adoption of extracorporeal membrane oxygenation machines in India, and rising cardiopulmonary disorders in Australia drive this region's growth.
Europe is the second-largest region after North America, with impressive market growth. The extracorporeal membrane oxygenation machine's market size was worth USD 95.87 million in 2024 and reached USD 114.07 billion by 2029. The market is estimated to grow with a CAGR of 4.39% during the forecasting timeline. According to Eurostat, in 2013, around 6.5 million people are affected by respiratory diseases. The surging investments from public and private organizations for research and development activities, growing demand for healthcare services, and stimulating demand for advanced technologies bolster the market growth. The U.K. is on top in ruling the ECMO market.
However, the Asia-Pacific ECMO market is expected to grow with the highest CAGR growth rate during the historic period. The government and other private organizations spend a considerable amount on developing healthcare facilities, raising awareness among people, and adopting ECMO machines designed with the latest technologies intensifying the market growth during the assessment period. Countries like China, India, and Japan, the ECMO market to have a promise growth rate. In China, the ECMO growth is due to stimulating cardiac complaints. India and Japan, acceptable reimbursement policies, climbing applications, and extracorporeal membrane oxygenation machines are adopted. In Australia, accentuating cardiopulmonary sickness bolsters the ECMO market growth. China has developed its first small and lightweight ECMO for treating COVID-19 patients in critical condition. In 2019, the ECMO machine was adopted by more than 5000 cases.
The ECMO market in Latin America to have a constant growth rate. Brazilian ECMO is the leading country in the region. It is a life-supporting device used in critical patients with pulmonary and cardiac and cardiac failure. The countries like Brazil, Mexico, and the Rest of LATAM balance the ECMO system in the area. According to the World Health Organization (WHO), approximately 85,961 deaths occurred in Mexico caused by ischemic heart disease. In 2017, Mexico showed the first successful bilateral lung transplant using the ECMO systems.
MEA region to have notable growth rate in the ECMO market. The flourishing adoption of an unhealthy lifestyle, increasing tobacco consumption in both females and males, further aiding the market growth. In countries like Saudi Arabia and Kuwait, the ECMO market growth is because of the burgeoning number of patients diagnosed with kidney failure and related heart diseases. The Saudi Arabian country is a roaring economy with fast growth.
Noteworthy companies dominating the global extracorporeal membrane oxygenation machine market profiled in this report are Getinge Group, Medtronic plc, LivaNova PLC, XENIOS AG, Terumo Corporation, MicroPort Scientific Corporation, NIPRO Corporation, OriGen Biomedical Inc., ALung Technologies Inc., and EUROSETS S.r.l.
The major market players are intensively developing the advanced technologies in ECMO.
By Modality
By Application
By Region
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region